The report on the first two patients enrolled in the CLIMB-THAL 111 and CLIMB-SCD 122 studies, one β°/β+ thal and one βS/βS SCD patient, showed a rapid rise in HbF and Hb levels after infusion of autologous CD34+ gene-edited cells, a pancellular distribution of HbF at the level of RBCs, and the permanence of gene-edited cells in peripheral blood [79]. This evidence concerns the gene GSTM1 and Schnyder corneal dystrophy.